AP
BIO icon

Antipodes Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Antipodes Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.2K Buy
+113
New +$32.1K ﹤0.01% 124

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Antipodes Partners's BIO Position: Q2 2026 in Review

Antipodes Partners opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 113 shares worth $33.2K. The stake represents ﹤0.01% of the portfolio and ranks #124 among its holdings.

397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Antipodes Partners held 113 shares of Bio-Rad Laboratories Class A worth $33.2K as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new Antipodes Partners position in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Antipodes Partners's portfolio in Q2 2026, its #124 holding.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.